Resources

In this guest blog, Lee Smith and Spiros Servos argue that early-stage biotech leaders who secure investment in 2026 are those who integrate commercial thinking early, aligning science, clinical strategy and market realities into a credible narrative for investors.

In this guest blog, Dan Stanton, Trade Media Expert at Sartorius Bioprocess Solutions, discusses how tight funding, manual tech transfer and product specific analytics are keeping cell and gene therapies (CGTs) from realising their potential.

Back from our Easter break, we’re hitting the ground running with an update on the publication of agreed text underpinning the UK-US pharmaceuticals agreement.

Each month, our Policy and Public Affairs team will showcase how we are championing members’ voices in Government and Parliament.

Lewis Miles discusses changes to EMIs, EISs and VCTs coming into force.

In this guest blog, Paul Jeffrey, Director of the GFIL/Cranfield Technology Accelerator at Cranfield Water Science Institute, explains how engineering biology solutions for environmental applications face unclear and complex regulatory pathways.

In this guest blog, Rubin Joshi, Business Development Manager at Aldevron, explains how scaling adeno-associated virus (AAV) manufacturing remains a major bottleneck for gene therapy development.

This guest blog from Cam Watson, biosolutions startup advisor, draws on a broader analysis of Japan’s biosolutions ecosystem, examining company formation, corporate engagement, manufacturing capacity and growth-stage funding dynamics.

I’m pleased to share that we are part of a new Government and industry joint taskforce to drive innovation in the UK’s commercial environment for medicines, announced last week as part of government ambitions for the Life Sciences Strategy.

In this blog, Linda Bedenik, our Head of Biosolutions and International Policy, and Maddie Cass, our Policy and Public Affairs Manager, reflect on the tireless work they have done, and will continue to do, to propel innovative biosolutions in the UK nationally and across Europe.

In this blog, Jaime Eaton, reflects on this month's Community Connects series, bringing together diverse expertise to tackle the most pressing challenges in our sector.

In this blog, Kate Barclay, Skills Strategy Consultant at BIA, shares the impact BIA member evidence has on the UK’s Skilled Worker Visa.

There are a number of significant moving pieces right now in the sector, including the major strategic shift at UKRI and Innovate launched last Thursday.

BIA BioSolutions is here: a new strategic platform dedicated to championing the UK’s engineering biology ecosystem beyond health. Discover how we are bridging the gap between world-class science and industrial scale to drive global sustainability.

The launch of the NIHR Industry hub last week, the launch of UKRI/Innovate strategy this Thursday and a landmark Mansion House event tomorrow all signal forward momentum on Industrial Strategy.

In this guest blog, Valerie Pinkerton, UK TNFD & Transition Plans Lead at the Green Finance Institute, explores why nature-related risks are becoming increasingly important for the pharmaceutical and biotechnology sector.

BIA member Asma Aslam, Senior Corporate Tax Manager at Frazier & Deeter, explores how a period of tighter capital and greater scrutiny has reshaped expectations around execution, value creation and operational discipline.

In this week’s update, we explore the growing momentum of the Health Data Research Service (HDRS), celebrate the resilience of our community following the "Big WiB" Women in Biotech event, and analyse the sector's outlook following the Chancellor's Spring Statement.

Each month, our Policy and Public Affairs team will showcase how we are championing members’ voices in Government and Parliament.

In this guest blog, Dr David Montgomery, co-founder of PM Life Sciences, discusses the reality of UK-originated assets, companies and long-term economic returns ending up overseas despite record public investment and a world-class discovery base.